What Is IGF-1 LR3? Long R3 IGF-1 Explained

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

IGF-1 LR3 is a recombinant analogue of insulin-like growth factor 1 carrying two deliberate changes. Both names in the label point at them: Long for an N-terminal extension, R3 for an arginine substitution at position 3. Neither modification is aimed at the receptor.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

Key points

Two modifications: a 13-residue N-terminal extension and Glu3→Arg.
Purpose of the R3 change: reduced affinity for the IGF binding proteins.
Receptor: unchanged — the IGF-1 receptor, with the usual insulin receptor cross-talk.
Class: recombinant protein, roughly 83 residues, not a synthetic peptide.
Long-standing research reagent, used well beyond any single field.

The binding-protein problem

Most circulating IGF-1 is not free. It is bound to a family of IGF binding proteins, chiefly IGFBP-3 in complex with an acid-labile subunit. These proteins are not inert carriers: they extend half-life, restrict tissue access, and compete with the receptor for the ligand.

For an experimentalist this creates a measurement problem. Add IGF-1 to a system containing binding proteins and you cannot easily say how much reached a receptor. Results then depend on the binding-protein concentration in that particular system, which varies between media, cell lines and animals.

The R3 substitution is the answer. Residue 3 lies in the N-terminal region that participates in binding-protein interaction, so replacing glutamic acid with arginine lowers that affinity considerably while leaving receptor binding largely intact. The result is an analogue whose available fraction is far less dependent on the binding-protein content of the system.

What the two modifications do

Modification	What it is	Intended effect
Long (L)	13-residue N-terminal extension from methionyl porcine growth hormone	Originates in the recombinant expression construct; aids production and handling
R3	Glu3 → Arg3	Reduced IGFBP affinity, so a greater free fraction
Combined effect	—	A reagent whose receptor availability is more predictable across systems

Note what is not modified: the receptor-binding surface. This is a pharmacokinetic and bioavailability modification, not a change in what the molecule tells a cell. Secondary descriptions sometimes present LR3 as “more potent”, which conflates a higher free fraction with a different intrinsic activity. They are not the same thing, and the distinction matters when comparing dose-response curves across papers.

Published uses

Study	System	Why it is informative
Hadsell et al., 2008	Mouse lactation, prolonged	Uses Long-R3-IGF-I alongside growth hormone and links effects to mammary signalling and gene expression
Engel et al., 2025	5XFAD mice, intranasal route	Reported amyloid plaque remodelling in cortex but no preservation of cognitive function — a clean example of a biomarker change without a functional one
Lu et al., 2023	Pichia pastoris expression	Production-side work: how the analogue is actually made

The 2025 paper deserves a note. Its negative functional result is reported in the title, which is unusual and useful. A structural or biomarker endpoint moving while a functional endpoint does not is one of the most common patterns in this literature, and papers that report it plainly are more valuable than those that stop at the biomarker.

The insulin receptor confounder

IGF-1 and insulin receptors are structurally related, and IGF-1 analogues retain measurable activity at the insulin receptor. For any experiment with a metabolic readout, this is a live confounder rather than a footnote: an observed change in glucose handling may run through either receptor. Receptor-specific blockade, or a cell line lacking one receptor, is the usual control.

Handling in the lab

Consideration	Practice
Form	Lyophilized protein; store sealed at −20 °C or colder
Reconstitution	Buffer per the data sheet; add gently down the vial wall, swirl, never vortex
Dilute solutions	Carrier protein (commonly BSA) to limit surface adsorption
Freeze–thaw	Aliquot on first reconstitution; proteins tolerate repeated thawing poorly
Identity and integrity	SDS-PAGE plus a receptor or signalling assay; intact mass alone will not show misfolding

The central caution is that a protein can lose activity with no visible change in the vial. An inactive result may be a handling artefact, so include a positive control that demonstrates the reagent was active on the day. For the short peptides in a mixed study set, our reconstitution calculator handles the concentration maths; protein buffers follow the data sheet instead.

Our IGF-1 LR3 research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report.

Open questions

How much residual IGFBP binding remains, and does it vary by binding-protein subtype?
What does the N-terminal extension do to receptor kinetics, if anything?
How should insulin receptor cross-activity be quantified in a given assay system?

Frequently asked questions

What does LR3 stand for in IGF-1 LR3?

L refers to the Long form, a 13-amino-acid extension at the N-terminus derived from methionyl porcine growth hormone. R3 refers to the substitution of arginine for glutamic acid at position 3 of the IGF-1 sequence. The full designation is Long R3 IGF-1.

Why was the Arg3 substitution made?

Position 3 is part of the region through which IGF-1 interacts with the IGF binding proteins. Substituting arginine there reduces binding-protein affinity, so a larger fraction of the molecule remains unbound in a system containing those proteins.

Is IGF-1 LR3 a peptide or a protein?

It is a recombinant protein of roughly 83 amino acids, produced in expression systems rather than by chemical synthesis. It is substantially larger than the short peptides most research catalogues list, and needs protein handling practice.

Does IGF-1 LR3 bind the same receptor as IGF-1?

Yes. The modifications target binding-protein interaction, not receptor binding, so it engages the IGF-1 receptor. It also retains the cross-reactivity with the insulin receptor characteristic of the IGF family, which is a confounder in metabolic experiments.

Is there published research using Long R3 IGF-1?

Yes. It has been used as a research reagent for decades, including in mouse lactation physiology, in recombinant expression studies, and more recently in an intranasal administration study in a mouse model of Alzheimer’s disease.

References

Hadsell DL, et al. Enhancement of maternal lactation performance during prolonged lactation in the mouse by mouse GH and long-R3-IGF-I is linked to changes in mammary signaling and gene expression. J Endocrinol. 2008. PMID: 18577570 https://pubmed.ncbi.nlm.nih.gov/18577570/
Engel MG, et al. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. J Alzheimers Dis. 2025. PMID: 39610283 https://pubmed.ncbi.nlm.nih.gov/39610283/
Lu Z, et al. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Appl Microbiol Biotechnol. 2023. PMID: 37261455 https://pubmed.ncbi.nlm.nih.gov/37261455/